Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials

Table 4 Correlations Between Patient Reported Measures and the Psoriasis Area and Severity Index (PASI) and Overall Lesion Severity Scale (OLS) at Baseline and at Week 12.

	STUDY A				STUDY B
	Baseline		Week 12		Baseline		Week 12
Patient-reported outcome measure	PASI	OLS	PASI	OLS	PASI	OLS	PASI	OLS
PSA Frequency	0.19	0.19	0.57	0.60	0.19	0.22	0.53	0.58
PSA Severity	0.16	0.16	0.55	0.59	0.19	0.23	0.54	0.58
DLQI Total Scale	0.20	0.18	0.51	0.48	0.25	0.19	0.59	0.58
DLQI Symptoms and Feelings Subscale	0.17	0.16	0.54	0.55	0.18	0.18	0.56	0.61
DLQI Daily Activities Subscale	0.10^b	0.12^a	0.44	0.44	0.20	0.12^a	0.51	0.50
DLQI Leisure Subscale	0.11^b	0.08	0.39	0.32	0.21	0.13^a	0.47	0.46
DLQI Work and School Subscale	0.18	0.15	0.37	0.34	0.19	0.16	0.35	0.32
DLQI Personal Relationship Subscale	0.13^a	0.13^a	0.31	0.29	0.11^a	0.10^b	0.41	0.36
DLQI Treatment Subscale	0.27	0.19	0.48	0.43	0.29	0.24	0.53	0.47
NPF Itch Scale	n/a	n/a	n/a	n/a	0.16	0.17	0.52	0.54
VAS Itch Scale	0.14^a	0.14^a	0.53	0.54	n/a	n/a	n/a	n/a

All correlations are significant at p < 0.001 unless otherwise noted ^ap < 0.01. ^bp < 0.05.

ISSN: 1477-7525